Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Week radiation blasts recurrent breast cancer, spares healthy tissue

NCT ID NCT05592938

Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether a 1-week course of partial breast radiation is safe and effective for women who have had a breast cancer recurrence after prior whole-breast radiation. Participants will receive targeted radiation after breast-conserving surgery to remove the new tumor. The goal is to avoid mastectomy while keeping side effects low.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 171 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * In-breast recurrence or new primary (ductal carcinoma in situ (DCIS) or invasive carcinoma) * Tumour \<3.0 cm in greatest diameter on pathologic examination, including both invasive and non-invasive components * \>5 years after completion of prior adjuvant whole or partial breast radiotherapy (prior nodal radiotherapy permitted) * Clinically node negative * Negative margins (no tumour on ink) * Recovered from surgery with the incision completely healed and no signs of infection Exclusion Criteria: * Multicentric disease (patients with multifocal breast cancer in the same quadrant are eligible) * Tumour histology limited to lobular carcinoma only * T4 disease * Node positive or distant metastatic disease * Serious non-malignant disease (cardiovascular, pulmonary, systemic lupus erythematosus, scleroderma), which would preclude radiation treatment * Currently pregnant or lactating * Presence of an ipsilateral breast implant or pacemaker * Unable to commence radiation within 16 weeks of breast-conserving surgery (or last surgical procedure on the breast) or within 12 weeks from last cycle of adjuvant chemotherapy * Unable to clearly define the surgical cavity (oncoplastic procedures are permitted provided the tumor bed is well delineated with surgical clips). * Psychiatric disorders which would preclude obtaining informed consent or adherence to protocol * Grade II or more late skin toxicity from prior radiation evaluated and graded using CTCAE v5.0 * Current or prior diagnosis of bilateral breast cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast cancer recurrent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.C.Camargo Cancer Center

    RECRUITING

    São Paulo, São Paulo, 105401, Brazil

  • AOU Careggi - Florence University Hospital

    RECRUITING

    Florence, Italy

  • CHU de Québec-Université Laval

    RECRUITING

    Montreal, Quebec, G1G 5X1, Canada

  • Centre hospitalier de l'Université de Montréal

    RECRUITING

    Montreal, Quebec, H2X 3E4, Canada

  • Clinica IRAM

    RECRUITING

    Vitacura, Santiago Metropolitan, 7630370, Chile

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

  • Hôpital Maisonneuve-Rosemont - CIUSSS de l'Est-de-l'Île-de-Montréal

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • King Hussein Cancer Centre

    RECRUITING

    Amman, Jordan, Jordan

  • Lakeridge Health

    RECRUITING

    Oshawa, Ontario, L1G 2B9, Canada

  • London Health Science Centre - Verspeeten Family Cancer Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Odette Cancer Centre

    RECRUITING

    Toronto, Ontario, M4N 3M5, Canada

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G2C4, Canada

  • Royal Victoria Regional Health Centre

    RECRUITING

    Barrie, Ontario, L4M 6M2, Canada

  • Tel-Aviv Sourasky Medical Centre

    RECRUITING

    Tel Aviv, Israel

  • The Aga Khan University

    RECRUITING

    Nairobi, Kenya

  • Universitiy Malaya Medical Centre

    RECRUITING

    Kuala Lumpur, Malaysia

  • Virgina Community University Massey Comprehensive Cancer Center

    RECRUITING

    Richmond, Virginia, 23298-0037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.